Study #2022-0118
A Phase 1b/2 basket study of ACR-368 as monotherapy and in combination with gemcitabine in adult subjects with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon OncoSignature® Status
MD Anderson Study Status
Enrolling
Treatment Agent
ACR-368, Diagnostic Test: OncoSignature, Gemcitabine
Description
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
Study phase:
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-807-9574
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.